2024 Precision biosciences inc stock - Avidity Biosciences Inc (NASDAQ:RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the fir... Avidity Biosciences Inc (NASDAQ:RNA) shares are trading higher Wednesday after the company...

 
Find the latest Pressure BioSciences, Inc. (PBIO) stock quote, history, news and other vital information to help you with your stock trading and investing.. Precision biosciences inc stock

DURHAM, N.C.--(BUSINESS WIRE)--Nov. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish financial results for the third quarter 2023 and provide a ...Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis.Precision BioSciences, Inc., an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including ...On December 4, 2023, Precision Biosciences made a groundbreaking announcement in the esteemed journal Nature Metabolism. The publication highlighted their latest preclinical research, providing strong support for the advancement of the PBGENE-PMM in vivo gene editing program. This program is specifically designed to address M.3243-associated …Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation.Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings PreviewSome of the losses seen by insiders who purchased US$162k worth of Precision BioSciences, Inc. (NASDAQ:DTIL) shares over the past year were recovered after the stock increased by 13% over the past ...Web7.24%. $256.56M. AEterna Zentaris Inc. 8.87%. $10.73M. RNA | Complete Avidity Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.On November 6, 2023, the stock price of Precision BioSciences Inc, ticker symbol DTIL, was at 0.41. However, according to data from CNN Money, analysts are predicting a significant increase in the stock’s value. Four analysts have offered 12-month price forecasts for Precision BioSciences Inc, with a median target of 3.00.Precision BioSciences (DTIL Quick Quote DTIL - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 27.5% over the past four weeks, the stock looks ...Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing …On Friday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock fall -5.64% to $0.40. On the same session, the stock had its day’s lowest price of $0.3853, but rose to a high of $0.44. Over the last five days, the stock has gained 4.63%. Precision Biosciences Inc shares have fallen nearly -66.40% since the year began.Precision Biosciences Inc (US:DTIL) has 116 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,897,221 shares.Precision BioSciences last posted its earnings results on November 7th, 2023. The reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The business earned $13.12 million during the quarter, compared to the consensus estimate of $7.50 million.On December 4, 2023, Precision Biosciences made a groundbreaking announcement in the esteemed journal Nature Metabolism. The publication highlighted their latest preclinical research, providing strong support for the advancement of the PBGENE-PMM in vivo gene editing program. This program is specifically designed to address M.3243-associated …BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT. HC Wainwright Lowers Price Target on Precision BioSciences to $17 from $20, Keeps Buy Rating. Nov. 10. MT. Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing …Nov 21, 2023 · Get Precision BioSciences Inc (DTIL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Jan 24, 2022 · Even the best stock pickers will make plenty of bad investments. And there's no doubt that Precision BioSciences, Inc. (NASDAQ:DTIL) stock has had a really bad year. In that relatively short period, the share price has plunged 65%. Precision BioSciences may have better days ahead, of course; we've only looked at a one year period. Precision BioSciences Inc stock price live 0.2969, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the market session or assess the after hours quote.In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Prometheus Biosciences, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample …With a price-to-sales (or "P/S") ratio of 3.8x Precision BioSciences, Inc. (NASDAQ:DTIL) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in ...WebAbout Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life ... risks related to ownership of our common stock; ...Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure …WebGet the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions. In June 2022, Precision announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, ... Precision Biosciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts)Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?DURHAM, N.C., August 15, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion ...Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical ... risks related to ownership of our common stock and other important factors discussed under the caption “Risk ...Precision BioSciences, Inc. Stock price BOERSE MUENCHEN Equities PBS US74019P1084 Biotechnology & Medical Research Real-time BOERSE MUENCHEN. Other stock markets. 09:13:47 2023-11-21 am EST 5-day change 1st Jan Change ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific presentation of preclinical data from its PBGENE-HBV program.PBGENE-HBV is designed to potentially eliminate hepatitis B …About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its …Get the latest Pressure Biosciences Inc (PBIO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.WebCurrently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...Which Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), …We will never request to mail you a physical check for home office set up or payroll funds. If you are asked for such information, please contact our HR Team by emailing us at [email protected] to verify the legitimacy of the request. Agency recruiters interested in working with us can apply to join our RecruitiFi community.DURHAM, N.C.--(BUSINESS WIRE)--Aug. 15, 2023-- Precision BioSciences, Inc. ... including fluctuations in our stock price, and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, ...Precision BioSciences Annual Revenue Estimates (Precision BioSciences) The company’s market cap is about $152M, so that would be a roughly 0.3x forward price-to-sales. Considering the industry ...Precision BioSciences, Inc. (NASDAQ:DTIL) is definitely on the radar of institutional investors who own 49% of the companySee Precision BioSciences, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. DURHAM, N.C., April 13, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...WebNov 29, 2023 · The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks. On average, Wall Street analysts predict. that Precision Biosciences's share price could reach $2.50 by Sep 19, 2024. The average Precision Biosciences stock price prediction forecasts a potential upside of 472.08% from the current DTIL share price of $0.44.WebPrecision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Stock analysis for Precision BioSciences Inc (DTIL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and …Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. ... as well as an equity investment by Lilly of $35 million in Precision's ...See Precision BioSciences, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy.Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share. Precision BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates. Read More.Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...Get the latest Precision BioSciences Inc (DTIL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.For more information about our programs, see our current corporate deck.WebWe credit much of our successes not only to our technical know-how, but our commitment to our team and our culture. Precision BioSciences utilizes its proprietary ARCUS Genome Editing method to overcome cancers, cure genetic diseases, and enable development of safer food.Get the latest stock price for Precision BioSciences Inc. (DTIL:US), plus the latest news, recent trades, charting, insider activity, and analyst ratings.The inducement award consists of an option to purchase (“stock option”) 160,000 shares of Precision’s common stock, par value $0.000005 (the “Common …Nov 6, 2023 · Precision BioSciences Inc, a biotechnology company, has been attracting attention from investors due to its potential for growth. On November 6, 2023, the stock price of Precision BioSciences Inc, ticker symbol DTIL, was at 0.41. However, according to data from CNN Money, analysts are predicting a significant increase in the stock’s value. View 13F filing holders of Precision BioSciences Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers.Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.The inducement award consists of an option to purchase (“stock option”) 160,000 shares of Precision’s common stock, par value $0.000005 (the “Common Stock”), which was granted to an ...WebWhich Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), …Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Find the latest Pressure BioSciences, Inc. (PBIO) stock quote, history, news and other vital information to help you with your stock trading and investing.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. ... The increase in weighted average shares of common …Based on 4 Wall Street analysts offering 12 month price targets for Precision BioSciences in the last 3 months. The average price target is $2.63 with a high ...Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close $0.3551 Advanced Charting... DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ...Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023 ... Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select …Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. ... The increase in weighted average shares of common …The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. …Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding Nov 9, 2023 · On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00. DURHAM, N.C., July 27, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies ...DURHAM, N.C.--(BUSINESS WIRE)--Dec. 11, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced program updates across its allogeneic CAR T cell therapy …WebPrecision BioSciences Inc share price live 0.4366, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the …DURHAM, North Carolina, April 1, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the closing of its initial public offering of 9,085,000 shares of common stock, which includes the full exercise of …Precision biosciences inc stock

Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3900 -0.0099 (-2.48%) At close: 04:00PM EST. 0.3896 -0.00 (-0.10%) After hours: 07 .... Precision biosciences inc stock

precision biosciences inc stock

Real time Precision BioSciences (DTIL) stock price quote, stock graph, ... Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies ...WebInformation on stock, financials, earnings, subsidiaries, investors, and executives for Precision BioSciences. Use the PitchBook Platform to explore the full profile. ... Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, A. Biotechnology. Durham, NC. 115 As of 2023 00000 ...WebWe note from Precision Biosciences Inc’s average daily trading volume that its 10-day average is 1.36 million shares, with the 3-month average coming to 1.15 million. Precision Biosciences Inc stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.50.Mol Cancer Res. 2019;17 (2):356-369. The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established. Arcus Biosciences is evaluating novel combinations of investigational medicines in early- and late ...WebSAN DIEGO, Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the …Avidity Biosciences Inc (NASDAQ:RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the fir... Avidity Biosciences Inc (NASDAQ:RNA) shares are trading higher Wednesday after the company...Nov 28, 2023 · Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board ... DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.About …When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors.Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Precision's platform and products are protected by a comprehensive portfolio including more than 80 patents to date. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform. ARCUS is a …Get the LIVE share price of Precision BioSciences Inc(DTIL) and stock performance in one place to strengthen your trading strategy in US stocks.The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks.If you are looking for stocks with good return, Precision Biosciences Inc stock can be a bad, high-risk 1-year investment option. Precision Biosciences Inc real time quote is equal to 0.363 USD at 2023-12-03, but your current investment may be devalued in the future. ...WebPrecision BioSciences Completes Spin-Out of Elo Life Systems. December 21, 2021 07:00 AM Eastern Standard Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ...Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...Precision's platform and products are protected by a comprehensive portfolio including more than 80 patents to date. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a …WebGet the LIVE share price of Precision BioSciences Inc(DTIL) and stock performance in one place to strengthen your trading strategy in US stocks.Nov 17, 2023 · In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ... Precision BioSciences, Inc. : DTIL Stock Price | US74019P1084 | MarketScreener. Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 …Precision BioSciences, Inc. Common Stock (DTIL) Stock Price, Quote, News & History | Nasdaq MY QUOTES: DTIL Edit my quotes Precision BioSciences, Inc. Common Stock (DTIL)...On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary …Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ... With Precision Biosciences stock trading at $0.41 per share, the total value of Precision Biosciences stock (market capitalization) is $49.24M. Precision Biosciences stock was originally listed at a price of $17.44 in Mar 28, 2019. If you had invested in Precision Biosciences stock at $17.44, your return over the last 4 years would have been ...View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ. DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...See the latest Precision BioSciences Inc stock price (DTIL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Nov 6, 2023 · Precision BioSciences Inc, a biotechnology company, has been attracting attention from investors due to its potential for growth. On November 6, 2023, the stock price of Precision BioSciences Inc, ticker symbol DTIL, was at 0.41. However, according to data from CNN Money, analysts are predicting a significant increase in the stock’s value. H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences ( DTIL – Research Report) today and set a price target of $17.00. The company’s shares opened today at ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Precision BioSciences Inc stock is down -74.15% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives DTIL stock a score of 34 out of a possible 100.Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings PreviewWeighted average shares of common stock outstanding were approximately 110.8 million for the quarter ended September 30, 2022, as compared to approximately 59.7 million for the quarter ended September 30, 2021. ... Precision BioSciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per …Olivier Le Moal. Precision BioSciences ( NASDAQ: DTIL) said it received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) related to a PCSK9-specific ARCUS nuclease. The U.S ...WebPrecision BioSciences Inc share price live 0.4366, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Precision BioSciences Inc real time stock price chart below ...What are individual investors saying about Precision BioSciences? View the latest DTIL social media trends at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the …WebPrecision BioSciences, Inc. (NASDAQ:DTIL) shareholders should be happy to see the share price up 15% in the last month. But that is meagre solace in the face of the shocking decline over three years.Web(RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that decreased from last year and missed the Street estimates.... (RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that de...Stock analysis for Precision BioSciences Inc (DTIL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and …Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings PreviewSee the latest Precision BioSciences Inc stock price (DTIL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Nov 29, 2023 · The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks. On Monday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock jump 2.61% to $0.45. On the same session, the stock had its day’s lowest price of $0.44, but rose to a high of $0.4695. Over the last five days, the stock has gained 30.61%. Precision Biosciences Inc shares have fallen nearly -62.35% since the year began.Precision BioSciences has sold its lead cell therapy asset as the company shifts focus exclusively to gene editing. ... Precision's stock, for instance, closed Monday at $0.45 a share, ...DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its …This could make Precision BioSciences Inc’s stock more attractive for value investors. Now, let’s assess Precision BioSciences Inc’s EV/EBITDA ratio, also known as enterprise multiple. At 1.0, when compared to the industry median of 0.7, the company may be considered overvalued in relation to its peers. Value investors could …Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...Precision BioSciences last posted its earnings results on November 7th, 2023. The reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The business earned $13.12 million during the quarter, compared to the consensus estimate of $7.50 million.Dec 21, 2021 · DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary ... Precision BioSciences, Inc. : DTIL Stock Price | US74019P1084 | MarketScreener. Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 …Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary …Find real-time DTIL - Precision BioSciences Inc stock quotes, company profile, news and forecasts from CNN Business.. Aarp dental insurance plan by delta dental